Insmed Inc (INSM)vsKyntra Bio, Inc. (KYNB)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
KYNB
Kyntra Bio, Inc.
$6.79
+0.59%
HEALTHCARE · Cap: $28.85M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 9317% more annual revenue ($606.42M vs $6.44M). KYNB leads profitability with a 28.5% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
KYNB
Avoid26
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Keeps 28 of every $100 in revenue as profit
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Revenue declined 59.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : KYNB
The strongest argument for KYNB centers on Profit Margin. Profitability is solid with margins at 28.5% and operating margin at -10.6%.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : KYNB
The primary concerns for KYNB are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while KYNB is a declining play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
KYNB generates stronger free cash flow (-18M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 26/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Kyntra Bio, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is headquartered in San Francisco, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?